Autolus claims a CAR-T win at EHA; Imago touts two PhII trial wins for rare disease drug
Presentations at the European Hematology Association began Friday, with Autolus Therapeutics revealing data they say continue to show the benefit of their CAR-T program.
The Autolus program, known as 0be-cel, achieved a 100% complete remission rate in a cohort of indolent B Cell Non-Hodgkin lymphoma patients, with all nine treated patients hitting the mark as of the May 17 cutoff. Another three patients are still awaiting treatment, while a fourth enrolled individual died due to a Covid-19 infection.
At a median follow-up of six months and ranging from four to 8.1 months, eight of nine patients were disease free at their last follow-up. One individual relapsed at month 6 but was rescued with radiotherapy. The Covid-19 patient had achieved complete remission, Autolus says, at 5.6 months.
Additionally, in another cohort for acute lymphoblastic leukemia, 17 of 20 patients saw MRD-negative complete remission after one month. Friday’s news comes after Autolus chopped 20% of its staff in January and set out to find a new partner for its CAR-T program. — Max Gelman
Imago announces results from 2 PHII trials for bomedemstat
Two Phase II studies of bomedemstat in patients received positive results, Imago BioSciences announced Friday.
In a study in patients with essential thrombocythemia, a rare disorder in which the body produces too many platelets, the data showed that 83% of the 12 patients dosed for more than six weeks showed a significant reduction of platelet counts. The drop happened while patients maintained stable hemoglobin levels, the company said.
Meanwhile, the data from a study in patients with advanced myelofibrosis — a type of bone cancer that disrupts the body’s normal production of blood cells — 94% of patients showed a reduction of 50% or more in symptoms. In 34 patients evaluated for mutant allele frequencies, the number decreased in 44% of patients and remained the same in 47%, with no new mutations in the 660 days that followed.
In the press release, Imago CMO Wan-Jen Hong said:
These updated clinical results reveal that bomedemstat continues to offer distinct clinical benefits for patients with advanced MF, showing overall improvement in total symptom scores, spleen volumes and anemia. The study is now fully enrolled, so we look forward to sharing our cumulative data as we continue to advance this investigational program for patients who have few therapeutic alternatives.